| Name | Title | Contact Details |
|---|---|---|
Anne-Marie Tucker |
Chief Technology Officer | Profile |
Health Union integrates the power of human connection with technology to unite people in the shared experiences of life with chronic health conditions. For almost a decade, Health Union has done the hard work every day to bring people living with chronic conditions together. Through a unique and genuine approach to listening and understanding all aspects of health experiences, Health Union`s open, online communities provide a safe place for people to learn, connect and share. In doing so, social interactions evolve into meaningful health conversations. At the same time, these communities offer healthcare companies countless opportunities to understand how to reach and engage people living with these conditions in smarter, more effective ways. Today, the Health Union family of brands includes online health communities for chronic conditions in a range of categories including primary care, immunology, oncology and neurodegenerative/genetic conditions. Among them are Migraine.com, MultipleSclerosis.net, Endometriosis.net and LungCancer.net to name a few. Health Union is dedicated to making an impact on the lives of people with chronic health concerns. In 2018, that focus has been recognized. The company was named among the top 15 percent of the Inc. 5000 list of fastest-growing private companies in America and topped the list of both Philly.com`s “Top Workplaces” and Philadelphia Business Journal`s “Best Places to Work.”
Covaris is a company that provides tools and technologies to improve pre-analytical sample preparation, enable novel drug formulations, and manage compounds in the drug discovery process. Their technological foundation is based on their proprietary and...
Hospice El Paso, Inc. is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Muki Baum Association is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.